INMED PHARMACEUTICALS INC. Income Tax Expense
INMED PHARMACEUTICALS INC. (INM) reported Income Tax Expense of $7.10 thousand for the 12-month period ending 2024-06-30, per its S-4 filed 2026-07-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-07-02
- INMED PHARMACEUTICALS INC. income tax expense (benefit) for the quarter ending 2022-09-30 was $6.80K.
- INMED PHARMACEUTICALS INC. income tax expense (benefit) for fiscal 2023 was $13.10K.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|
| 2024-06-30 | $7.10K S-4 · filed 2026-07-02 | |
| 2023-06-30 | $13.10K 10-K · filed 2024-09-30 | |
| 2022-09-30 | $6.80K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |